New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1142-1148

  Chiu, M J ^a   Yang, S Y ^b,e   Chen, T F ^a   Chieh, J J ^b   Huang, T Z ^a   Yip, P K ^c,d   Yang, H C ^a   Cheng, T W ^a   Chen, Y F ^f   Hua, M S ^a   Horng, H E ^b,g  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^c CARDINAL TIEN HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e MAGQU CO LTD   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NONE   (Taiwan)

Author keywords

Alzheimer's disease; Immunomagnetic reduction assay; Mild cognitive impairment; Nanoparticles; Plasma beta amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BIOASSAY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMAGNETIC REDUCTION ASSAY; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 84874819362     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142967     Document Type: Article

References (44)

1. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75: 143-151 (2010).
2. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H et al. Cerebrospinal fluid-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66: 382-389 (2009).
3. Cedazo-Mnguez A, Winblad B. Biomarkers of Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspect. Exp Gerontol 45: 5-14 (2010).
4. Bermejo-Pareja F, Anteguera D, Vargas T, Molina JA, Carro E. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. BMC Neurol 10: 108 (2010).
5. Qkereke OI, Xia W, Irizarry MC, Sun X, Qui WQ, Fagan AM, et al. Performance characteristics of plasma amyloid40 and 42 assays. J Alzheim Dis 16: 277-285 (2009).
6. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends in Biotechnol 29: 26-32 (2010).
7. Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, et al. High levels of circulating A 42 are sequestrated by plasma proteins in Alzheimer's disease. Biochem Biophys Res Comm 257: 787-791 (1999).
8. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not refelct brain Abeta levels. J Neuropathol Exp Neurol 66: 264-271 (2007).
9. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma abeta42/abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer's disease. Arch Neurol 64: 354-362 (2007).
10. Irizarry MC. Biomarkers for Alzheimer's disease in plasma. NeuroRx 1: 226-234 (2004).
11. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, et al. Amyloid peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223: 366-370 (2010).
12. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta (1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5: 655-660 (2006).
13. Zetterberg H, Blennow K, Hanse E. Amyloid and APP as biomarkers for Alzheimer's disease. Exp Gerontol 45: 23-29 (2010).
14. Kötitz R, Weitschies W, Trahms L, Brewer W, Semmler WJ. Determination of the binding reaction between avidin and biotin by relaxation measurements of magnetic nanoparticles. J Magn Magn Mater 194: 62-68 (1999).
15. Horng HE, Yang SY, Huang YW, Jiang WQ, Hong CY, Yang HC. Nanomagnetic Particles for SQUID-based Magnetically Labeled Immunoassay. IEEE Trans Appl Supercond 15: 668-671 (2005).
16. Yang HC, Yang SY, Liao SH, Fang GL, Huang WH, Liu CH, et al. Magnetic relaxation measurement in immunoassay using hightransition-temperature superconducting quantum interference device system. J Appl Phys 99: 124701 (2006).
17. Krause HJ, Wolters N, Zhang Y, Offenhäusser A, Miethe P, Meyer, MHF. Magnetic particle detection by frequency mixing for immunoassay applications. J Magn Magn Mater 311: 436-444 (2007).
18. Enpuku K, Kuroda D, Ohba A, Yang TQ, Yoshinaga K, Nakahara T. Biological Immunoassay Utilizing Magnetic Marker and High Tc Superconducting Quantum Interference Device Magnetometer. J Appl Phys 42: L1436 (2003).
19. Yang CC, Yang SY, Chieh JJ, Horng HE, Hong CY, Yang HC, et al. Bio-functionalzied magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. Accepted in ACS Chem Neurosci 2(9): 500-515 (2011).
20. Chiu MJ, Horng HE, Chieh JJ, Liao SH, Chen CH, Shih BY, et al. Multi-channel SQID-based ultra-high-sensitivity in-vitro detections for biomarkers of Alzheimer's disease via immunomagnetic reduction. IEEE Trans Appl Supercond 21: 477-480 (2011).
21. McKhann G, Drachman D, Folstein M, Katzman D, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's type: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944 (1984).
22. Moroney J, Bagiella E, Desmond D, Hachinski V, Molsa P, Gustafson L, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 49: 1096-1105 (1997).
23. Hua MS, Chang BS, Lin KN, Yang JM, Lu SR, Chen and S.Y. Wechsler memory scale, 3rd ed. Chinese Behavioral Science Corporation, Taipei. (2005).
24. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Bri J Psychiatry 140: 566-572 (1982).
25. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives of Neurology 58: 1985-1992 (2001).
26. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-194 (2004).
27. Chen TF, Lin CC, Chen YF, Liu HM, Hua MS, Huang YC, et al. Diffusion tensor changes in patients with amnesic mild cognitive impairment and various dementias. Psychiatry Res 173: 15-21 (2009).
28. Chen TF, Chen YF, Cheng TW, Hua MS, Liu HM, Chiu MJ. Executive dysfunction and periventricular diffusion tensor changes in amnesic mild cognitive impairment and early Alzheimer's disease. Hum Brain Mapp 30: 3826-3836 (2009).
29. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid beta 34, 40, 42 species in cerebrospinal fluid: More of the same? Ann Neurol 58: 139-142 (2005).
30. Zetterberg H, Blennow K. Plasma A in Alzheimer's disease-up or down? Lancet Neurol 5: 638-639 (2006).
31. Mehta PD, Prittila T, Mehta SP, Seren EA, Aisen PS, Wisniewski M. Plasma and cerebral fluid levels of Amyloid proteins 1-40 and 1-42 in Alzheimer's disease. Arch Neurol 57: 100-105 (2000).
32. Richens JL, Urbanowicz RA, Metcalf R, Corne J, O'Shea P, Fairclough L. Quantitative validation and comparison of multiplex cytokine kits. J Biomol Screen 15: 562-568 (2010).
33. Eidem JK, Kleivdal H, Kroll K, Denslow N, van Aerlec R, Tyler C, et al. Development and validation of a direct homologous quantitative sandwich ELISA for fathead minnow (Pimephales promelas) vitellogenin. Aquat Toxicol 78: 202-206 (2006).
34. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, et al. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta 1-42. J Neurochem 75:1219-1233 (2000).
35. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214 (2003).
36. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 6: 291-301 (2004).
37. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, et al. Smith MA Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30, 447-450 (2001).
38. Weinreb O, Mandel S, Bar-Am O, Amit T. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm 118: 479-492 (2011).
39. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, et al. Systemic catabolism of Alzheimer's A 40 and A 42. J Biol Chem 279: 45897-45908 (2004).
40. Oprisiu R, Serot JM, Godegroy O, Black S, Fournier A. Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis. Lancet Neurol 5: 1000-1003 (2006).
41. Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, Wahlund LO, et al. The normal equilibrium between CSF and plasma amyloid beta level is disrupted in Alzheimer's disease. Neruosci Lett 427: 127-131 (2007).
42. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, et al. A peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5: 18-29 (2009).
43. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-beta dynamics are regulated by orexin and the sample sleep-wake cycle. Science 326: 1005-1007 (1995).
44. Lachno DR, Vanerstichele H, De Groote G, Kostanjevecki V, De Meyer G, Siemers ER, et al. The influence of matrix type, diurnal rhythm and sample collection on the measurement of plasma betaamyloid isoforms using the INNO-BIA plasma abeta forms multiplex assay. J Nutr Health Aging 13: 220-225 (2009)